Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #1241

    Ja det kan være et vigtigt studie.

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #1242

      Der er også noget om JNJs PD1 plus dara i fase 2/3. Men vel kun forsøgsdesign.

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #1243

        Genmab Announces Data to be Presented at 2018 ASCO Annual Meeting https://globenewswire.com/news-release/2018/04/25/1487380/0/en/Genmab-Announces-Data-to-be-Presented-at-2018-ASCO-Annual-Meeting.html

        1 Reply Last reply
        0
        • T Offline
          T Offline
          Thomas
          wrote on sidst redigeret af
          #1244

          Hvor tæt er TV potentielt på markedet? Husker jeg rigtigt at det måske er muligt at søge godkendelse på fase 2 data?

          1 Reply Last reply
          0
          • BulderB Offline
            BulderB Offline
            Bulder
            wrote on sidst redigeret af
            #1245

            Det har Winkel talt om ved flere lejligheder. Da der er et udækket behov for et medikament i metastatisk LMHK, vil muligheden være til stede, hvis data er gode nok. Men studiet er end ikke begyndt at rekruttere https://www.clinicaltrials.gov/ct2/show/NCT03438396?term=tisotumab+vedotin&rank=3 Så tidligst 2021 er hvad jeg har hørt.

            1 Reply Last reply
            0
            • SolsenS Offline
              SolsenS Offline
              Solsen
              wrote on sidst redigeret af
              #1246

              https://clinicaltrials.gov/ct2/show/NCT03357952?term=JNJ-63723283&rank=2 Pd1 plus dara har primary completion date 15. Marts i år....

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #1247

                Pudsigt, i pressemeddelelsen skriver Genmab at det er et fase 2/3 studie. På ct står det som fase 1?? https://clinicaltrials.gov/ct2/show/NCT03357952?term=mmy2036&rank=1 Men det er måske det, de mener med et multi-fase-studie. Og at effekt-delen i part 3 er nok til at file på? Der er jo pænt mange pts med.

                1 Reply Last reply
                0
                • T Offline
                  T Offline
                  Thomas
                  wrote on sidst redigeret af
                  #1248

                  Tak Bulder

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #1249

                    Det siger abstracts også...

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #1250

                      Det gør det jo noget mere interessant, hvis vi er så tæt på filing. Jeg er hele tiden gået ud fra, at det er et rent fase 1 safety studie.

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #1251

                        Jeg spørger Winkel på Q&A.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #1252

                          Jeg er lidt forvirret. I januar skriver Novod: We expect the first combo studies of JNJ-283 and Darzalex to be initiated in 2018. Og nu har vi pludseligt et fase 2/3 studie, som faktisk er færdigt!

                          1 Reply Last reply
                          0
                          • SolsenS Offline
                            SolsenS Offline
                            Solsen
                            wrote on sidst redigeret af
                            #1253

                            Tror du ikke det er solide han omtaler.

                            1 Reply Last reply
                            0
                            • BulderB Offline
                              BulderB Offline
                              Bulder
                              wrote on sidst redigeret af
                              #1254

                              Selvfølgelig. Tak Solsen 🙂

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #1255

                                Holdt foredrag i Svinningehallen her til aften. Genmab er stadig en folkeaktie. 🙂

                                1 Reply Last reply
                                0
                                • M Offline
                                  M Offline
                                  Mayflower
                                  wrote on sidst redigeret af
                                  #1256

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #1257

                                    Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

                                    favicon

                                    (www.fiercebiotech.com)

                                    1 Reply Last reply
                                    0
                                    • S Offline
                                      S Offline
                                      Sukkeralf
                                      wrote on sidst redigeret af
                                      #1258

                                      Måske også et lille slag i ansigtet til ADCT-301. For dem der følger Bergenbio så rart at det nye AXL ADCT-601 bruger den nye linker teknologi

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #1259

                                        Lidt fra Firstword: Final thoughts

                                        Of course, one of the most high-profile reckonings for an ADC- and the PBD dimers used by ADC Therapeutics- will come from Stemcentrx and AbbVie's highly anticipated TRITON study of Rova-T. Unfortunately, AbbVie has already signalled that the outcome with be poor for the small-cell lung cancer candidate (SCLC);

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #1260

                                          last month it disclosed some mixed data and indicated it would not be pursuing accelerated approval for the compound. That said, companies like ADC Therapeutics can be confident that as long as the readout isn't dripping with safety concerns, their platform should still have legs

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger